Drugs / eTIV_a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00481065 | Apr 2007 → Dec 2008 | avian influenza | Novartis | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00579345 Comparator | Oct 2007 → Jun 2008 | influenza | Novartis | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eTIV_a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00579345 ↗ |
| Known as | Agrippal() | “Adult and elderly subjects previously immunized with cell culture-derived (CCIV; Optaflu(®)) or egg-derived (TIV; Agrippal(®)) trivalent influenza vaccines” PMID 22418809 ↗ May 2012 |
| Known as | TIV | “Adult and elderly subjects previously immunized with cell culture-derived (CCIV; Optaflu(®)) or egg-derived (TIV; Agrippal(®)) trivalent influenza vaccines” PMID 22418809 ↗ May 2012 |
| Route | Intramuscular | “administered as 0.5 mL single dose in the deltoid muscle” NCT00579345 ↗ |